These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22044445)

  • 1. Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.
    Fischer K; Lewandowski D; Marijke van den Berg H; Janssen MP
    Haemophilia; 2012 May; 18(3):e241-6. PubMed ID: 22044445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
    Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M;
    Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
    Vézina C; Carcao M; Infante-Rivard C; Lillicrap D; Stain AM; Paradis E; Teitel J; Rivard GE;
    Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor development in non-severe haemophilia across Europe.
    Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
    Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
    Chalmers EA; Brown SA; Keeling D; Liesner R; Richards M; Stirling D; Thomas A; Vidler V; Williams MD; Young D;
    Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of inhibitors in haemophilia A.
    Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Güngör T; Kornhuber B
    Vox Sang; 1996; 70 Suppl 1():2-8. PubMed ID: 8869461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
    Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
    Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
    Strauss T; Lubetsky A; Ravid B; Bashari D; Luboshitz J; Lalezari S; Misgav M; Martinowitz U; Kenet G
    Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
    Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
    Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
    Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.
    Peerlinck K; Hermans C
    Haemophilia; 2006 Nov; 12(6):579-90. PubMed ID: 17083507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prevalence of inhibitor antibodies in the Canadian haemophilia population.
    Webert KE; Rivard GE; Teitel J; Carcao M; Lillicrap D; St-Louis J; Walker IR
    Haemophilia; 2012 May; 18(3):e254-9. PubMed ID: 22077390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of inhibitors in mild/moderate haemophilia A.
    Peerlinck K; Jacquemin M
    Haemophilia; 2006 Dec; 12 Suppl 6():43-7. PubMed ID: 17123393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.
    van Helden PM; Van Haren SD; Fijnvandraat K; van den Berg HM; Voorberg J
    Haemophilia; 2010 May; 16(102):35-43. PubMed ID: 20536984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.
    Iorio A; Fischer K; Makris M
    Br J Haematol; 2017 Jul; 178(1):20-31. PubMed ID: 28387451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.